SML4071

BAY-593

Name: BAY-593
Brand: SIGMA

≥95% (HPLC)

别名:

(R)-3,3,3-Trifluoro-2-methoxy-1-((R)-7-(2-methoxyphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-phenylpropan-1-one, (2R)-3,3,3-Trifluoro-2-methoxy-1-[(7R)-7-(2-methoxyphenyl)-3,9-diazaspiro[5.5]undec-3-yl]-2-phenyl-1-propanone, BAY 593, BAY593, GGTase-I inhibitor BAY-593, YAP1/TAZ pathway inhibitor BAY-593

登录查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:

C₂₆H₃₁F₃N₂O₃

化学文摘社编号:

2413020-56-9

分子量:

476.53

UNSPSC Code:

12352200

Assay:

≥95% (HPLC)

Form:

powder

Quality level:

100

主要文件

查看所有文档

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

100

Biochem/physiol Actions

BAY-593, a GGTase-I inhibitor, primarily targets the YAP1/TAZ signaling pathway, a crucial axis in cell proliferation and tumor progression. Notably, BAY593 alters the mRNA expression levels of YAP1/TAZ target genes including CYR61, CTCF, ANKRD1, and CD274, indicating its specific molecular action. In vitro studies reveal its IC50 values: 9.41 nM for MDA-MB-231 TEAD-luc, 0.564 µM for MDA-MB-231 proliferation, and 38.4 nM for HT-1080 proliferation. The efficacious in vivo dose was determined as 5 mg/kg (p.o., BID), in the PXF 541 pleuromesothelioma xenograft model, showcasing its therapeutic potential in cancer treatment.